Elsevier

Annals of Hepatology

Volume 18, Issue 1, January–February 2019, Pages 236-239
Annals of Hepatology

Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done

https://doi.org/10.5604/01.3001.0012.7931Get rights and content
Under a Creative Commons license
open access

Abstract

Nowadays, the retreatment of patients with Hepatitis C virus (HCV) genotype 3 (GT3) especially cirrhotic, who have already been treated with regimens containing a NS5A inhibitor represents a challenge. Use a novel retreatment option for patients with a difficult approach. We present three case reports of retreatment with a new combination of Direct-acting antivirals (DAAs), Sofosbuvir, Elbasvir/Grazoprevir in patients with GT3 with a previous failure with Sofosbuvir/Ledipasvir. All the cases achieved sustained virologic response (SVR) at week +12 without adverse effects. In our experience, this combo may represent an effective and safe option for these patients.

Key words

Hepatitis C virus
Treatment failure
Genotype 3
Sofosbuvir
Grazoprevir + Elbasvir

Cited by (0)